Cermin Dunia Kedokteran
Vol 46 No 12 (2019): Kardiovakular

Hasil Pengobatan Adjuvan Tamoxifen pada Pasien Kanker Payudara di RSUP Dr. M. Djamil Padang

Muhammad Fadhil (Profesi Dokter
Fakultas Kedokteran Universitas Andalas , Padang, Sumatera Barat, Indonesia)

Wirsma Arif Harahap (Bagian Bedah Divisi Bedah Onkologi
Fakultas Kedokteran Universitas Andalas , Padang, Sumatera Barat, Indonesia)

Dewi Rusnita (Bagian Anatomi, Fakultas Kedokteran Universitas Andalas , Padang, Sumatera Barat, Indonesia)



Article Info

Publish Date
02 Dec 2019

Abstract

Kanker payudara merupakan kanker yang paling banyak pada perempuan di dunia. Pada beberapa dekade terakhir, pengobatan adjuvan tamoxifen banyak digunakan. Penelitian ini bertujuan mengevaluasi disease-free survival, survival rate, dan efek samping pengobatan tamoxifen. Penelitian deskriptif retrospektif pada bulan September hingga Desember 2016 di RSUP Dr. M. Djamil Padang menggunakan data sekunder 100 sampel dari rekam medik bagian Bedah Onkologi RSUP Dr. M. Djamil Padang dan data primer melalui wawancara. Analisis dilakukan secara univariat dan metode Kaplan-Meier. Hasil penelitian ini didapatkan kelompok usia terbanyak adalah 50-59 tahun dengan rata-rata 52,3 tahun. Disease-free survival 5 tahun adalah 0,727 dan survival rate 5 tahun adalah 0,777. Efek samping paling banyak adalah hot flush (65%). Terdapat hubungan antara efek samping pengobatan tamoxifen dan disease free survival dengan nilai p=0,001 (p < 0,05) kekuatan hubungan sedang (r=0,376). Breast cancer is the most commonly diagnosed cancer among women worldwide. For the last few decades, adjuvant tamoxifen is the most preferred therapy. This research aims to evaluate the disease-free survival, survival rate, and side effects of tamoxifen therapy. This retrospective descriptive research was conducted in September until December 2016 at Dr. M. Djamil Padang Hospital using 100 secondary data samples from medical records of Surgical Oncology Dept., Dr. M. Djamil Padang Hospital and primary data through interviews. Univariate analysis and Kaplan-Meier method are used. The result shows that the largest age group is 50-59 years old with average 52.3 years old. The 5-year disease-free survival is 0.727 and 5-year survival rate is 0.777, the most frequent side effect is hot flush (65%). There is medium strength of the relationship (r = 0.376) between side effects of tamoxifen treatment with disease-free survival (p = 0.001 <0.05).

Copyrights © 2019






Journal Info

Abbrev

cdk

Publisher

Subject

Health Professions

Description

Cermin Dunia Kedokteran (CDK) is a Medical Journal published since 1974 and affiliated with PT Kalbe Farma Tbk. CDK is intended to help accommodate scientific publications and help increase and disseminate knowledge related to the development of medical science, pharmacy, and public health. CDK ...